Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines.

Headquartered in China’s southwestern city Kunming, Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines.

With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, Walvax produces efficacious, quality, innovative and affordable products to protect people from the world’s deadliest diseases, for the purpose of helping everyone live a healthy life.

Walvax has assembled a seasoned core management team consisting of entrepreneurial teams from CNBG and senior vaccine experts from MNCs, and over 210 doctor's or master's degree personnel.

Walvax has established advanced platforms for the research and development of polysaccharide and conjugate vaccines, recombinant protein and VLP vaccines, and mRNA vaccines. With COVID-19 pandemic raging globally, Walvax has led the efforts in developing 2 vaccinology for SARS-CoV-2 virus, which are mRNA vaccinology and recombinant subunit vaccinology. Meanwhile, Walvax has successfully developed 8 licensed vaccines (12 presentations), including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2), 23-valent pneumococcal polysaccharide (PPSV23), Group ACYW135 meningococcal polysaccharide vaccine(MPV ACYW135), Group A and C meningococcal polysaccharide vaccine (MPV AC), Group A and group C meningococcal conjugate vaccine (MCV AC), Haemophilus influenza type b conjugate vaccine (Hib), and Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP).

Till date, Walvax has 4 manufacturing centers in Yuxi, Beijing, Sichuan and Guangzhou, respectively. Located in Yuxi City which is about 62 miles (100 km) south of Kunming, Walvax's commercial manufacturing facility of 93,000 m² plant space is currently manufacturing all licensed and to be licensed vaccines. The annual capacity for a variety of vaccines at Yuxi facility is about 390 million doses.

Walvax’s products has been distributed to 31 provinces, more than 220 cities and more than 2,400 counties in China. Beyond China, Walvax has worked closely with business partners to reach overseas markets, and has been exporting vaccines to 20 countries, including Indonesia, Thailand, the United States, Morocco, Uzbekistan, Egypt, the Philippines, Bangladesh, Guinea, Nigeria, Senegal, Mauritius, Niger, India, Kyrgyzstan, etc.

In the global collaboration area, Walvax and its subsidiaries have been partnering with academic institutions, industry peers and international organizations. Hitherto, Walvax has received three grants worth US$ 8.5 million in total from the Bill & Melinda Gates Foundation to support WHO prequalification for the HPV2 and HPV9 in order to prepare for UNICEF procurement for Gavi countries, and to expedite pre-clinical research of Recombinant Subunit SARS-CoV-2 Vaccine as well. Walvax has also partnered with CEPI and expanded collaboration to develop COVID-19 multi-variant vaccine. In addition, HPV2 and MPV ACYW135 are under WHO-PQ assessment, while PCV13 is undergoing WHO-PQ preparations.